English

• 

• 1. [1] N. Siddiqui, S.K. Arya, W. Ahsan, B. Azad, Diverse biological activities of thiazoles: a retrospect, Int. J. Drug Dev. Res. 3 (2011) 55-67.[1] N. Siddiqui, S.K. Arya, W. Ahsan, B. Azad, Diverse biological activities of thiazoles: a retrospect, Int. J. Drug Dev. Res. 3 (2011) 55-67.

  2. [2] S.J. Kashyap, V.K. Garg, P.K. Sharma, et al., Thiazoles: having diverse biological activities, Med. Chem. Res. 21 (2012) 2123-2132.[2] S.J. Kashyap, V.K. Garg, P.K. Sharma, et al., Thiazoles: having diverse biological activities, Med. Chem. Res. 21 (2012) 2123-2132.

  3. [3] N. Siddiqui, M.F. Arshad, W. Ahsan, M.S. Alam, Thiazoles: a valuable insight into the recent advances and biological activities, Int. J. Pharm. Sci. Rev. Res. 1 (2009) 136-143.[3] N. Siddiqui, M.F. Arshad, W. Ahsan, M.S. Alam, Thiazoles: a valuable insight into the recent advances and biological activities, Int. J. Pharm. Sci. Rev. Res. 1 (2009) 136-143.

  4. [4] N.K. Shah, N.M. Shah, M.P. Patel, R.G. Patel, Synthesis, characterization and antimicrobial activity of some new biquinoline derivatives containing a thiazole moiety, Chin. Chem. Lett. 23 (2012) 454-457.[4] N.K. Shah, N.M. Shah, M.P. Patel, R.G. Patel, Synthesis, characterization and antimicrobial activity of some new biquinoline derivatives containing a thiazole moiety, Chin. Chem. Lett. 23 (2012) 454-457.

  5. [5] C.B. Guo, Z.F. Cai, Z.R. Guo, et al., Design, synthesis and in vitro evaluation of thiazole derivatives of ibuprofen as cyclooxygenase-2 inhibitors, Chin. Chem. Lett. 17 (2006) 325-328.[5] C.B. Guo, Z.F. Cai, Z.R. Guo, et al., Design, synthesis and in vitro evaluation of thiazole derivatives of ibuprofen as cyclooxygenase-2 inhibitors, Chin. Chem. Lett. 17 (2006) 325-328.

  6. [6] S.F. Cui, Y. Wang, J.S. Lu, G.L.V. Damu, C.H. Zhou, Recent advances in application of thiazole compounds, Sci. China: Chem. 42 (2012) 1105-1131.[6] S.F. Cui, Y. Wang, J.S. Lu, G.L.V. Damu, C.H. Zhou, Recent advances in application of thiazole compounds, Sci. China: Chem. 42 (2012) 1105-1131.

  7. [7] U. Galm, E. Wendt-Pienkowski, L.Y. Wang, et al., Comparative analysis of the biosynthetic gene clusters and pathways for three structurally related antitumor antibiotics bleomycin, tallysomycin and zorbamycin, J. Nat. Prod. 74 (2011) 526-536.[7] U. Galm, E. Wendt-Pienkowski, L.Y. Wang, et al., Comparative analysis of the biosynthetic gene clusters and pathways for three structurally related antitumor antibiotics bleomycin, tallysomycin and zorbamycin, J. Nat. Prod. 74 (2011) 526-536.

  8. [8] J. Zhong, Muscarine, imidazole, oxazole, and thiazole alkaloids, Nat. Prod. Rep. 20 (2003) 584-605.[8] J. Zhong, Muscarine, imidazole, oxazole, and thiazole alkaloids, Nat. Prod. Rep. 20 (2003) 584-605.

  9. [9] S. Carradori, D. Secci, A. Bolasco, et al., Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents, Eur. J. Med. Chem. 65 (2013) 102-111.[9] S. Carradori, D. Secci, A. Bolasco, et al., Synthesis and cytotoxicity of novel (thiazol-2-yl)hydrazine derivatives as promising anti-Candida agents, Eur. J. Med. Chem. 65 (2013) 102-111.

  10. [10] Y.J. Yang, Y.N. Yang, J.S. Jiang, et al., Synthesis and cytotoxic activity of heterocycle-substituted phthalimide derivatives, Chin. Chem. Lett. 21 (2010) 902-904.[10] Y.J. Yang, Y.N. Yang, J.S. Jiang, et al., Synthesis and cytotoxic activity of heterocycle-substituted phthalimide derivatives, Chin. Chem. Lett. 21 (2010) 902-904.

  11. [11] J.D. Moore, A. Potter, Pin1 inhibitors: pitfalls, progress and cellular pharmacology, Bioorg. Med. Chem. Lett. 23 (2013) 4283-4291.[11] J.D. Moore, A. Potter, Pin1 inhibitors: pitfalls, progress and cellular pharmacology, Bioorg. Med. Chem. Lett. 23 (2013) 4283-4291.

  12. [12] Y.Y. Xi, J. Jin, Y. Sun, et al., Design, synthesis and biological evaluation of novel diaryl ethers bearing a pyrimidine motif as human Pin1 inhibitors, Acta Pharm. Sin. 48 (2013) 1266-1272.[12] Y.Y. Xi, J. Jin, Y. Sun, et al., Design, synthesis and biological evaluation of novel diaryl ethers bearing a pyrimidine motif as human Pin1 inhibitors, Acta Pharm. Sin. 48 (2013) 1266-1272.

  13. [13] C. Liu, J. Jin, L. Chen, et al., Synthesis and biological evaluation of novel human Pin1 inhibitors with benzophenone skeleton, Bioorg.Med. Chem. 20 (2012) 2992-2999.[13] C. Liu, J. Jin, L. Chen, et al., Synthesis and biological evaluation of novel human Pin1 inhibitors with benzophenone skeleton, Bioorg.Med. Chem. 20 (2012) 2992-2999.

  14. [14] L.N. Zhu, J. Jin, C. Liu, et al., Synthesis and biological evaluation of novel quinazoline-derived human Pin1 inhibitors, Bioorg. Med. Chem. 19 (2011) 2797-2807.[14] L.N. Zhu, J. Jin, C. Liu, et al., Synthesis and biological evaluation of novel quinazoline-derived human Pin1 inhibitors, Bioorg. Med. Chem. 19 (2011) 2797-2807.

  15. [15] C.J. Zhang, Z.H. Zhang, B.L. Xu, Y.L. Wang, Recent advances in the study of Pinl and its inhibitors, Acta Pharm. Sin. 43 (2008) 9-17.[15] C.J. Zhang, Z.H. Zhang, B.L. Xu, Y.L. Wang, Recent advances in the study of Pinl and its inhibitors, Acta Pharm. Sin. 43 (2008) 9-17.

  16. [16] T. Fuchigami, T. Nonaka, Facile synthesis of 5-acyl-4-amino-2-ethoxythiazoles from an [ethoxy(thiocarbonyl)]cyanamide salt and α-halo ketones, J. Org. Chem. 48 (1983) 3340-3341.[16] T. Fuchigami, T. Nonaka, Facile synthesis of 5-acyl-4-amino-2-ethoxythiazoles from an [ethoxy(thiocarbonyl)]cyanamide salt and α-halo ketones, J. Org. Chem. 48 (1983) 3340-3341.

  17. [17] T. Fuchigami, M.Y. Yeh, T. Nonaka, H.J. Tien, Studies of cyanamide derivatives. Part 109. A convenient method for preparation of 4-aminothiazole compounds from alkoxythiocarbonylcyanamide salts, Bull. Chem. Soc. Jpn. 56 (1983) 3851-3852.[17] T. Fuchigami, M.Y. Yeh, T. Nonaka, H.J. Tien, Studies of cyanamide derivatives. Part 109. A convenient method for preparation of 4-aminothiazole compounds from alkoxythiocarbonylcyanamide salts, Bull. Chem. Soc. Jpn. 56 (1983) 3851-3852.

  18. [18] P. van der Peet, C.T. Gannon, I. Walker, et al., Use of click chemistry to define the substrate specificity of leishmania b-1,2-mannosyltransferases, ChemBioChem 7 (2006) 1384-1391.[18] P. van der Peet, C.T. Gannon, I. Walker, et al., Use of click chemistry to define the substrate specificity of leishmania b-1,2-mannosyltransferases, ChemBioChem 7 (2006) 1384-1391.

  19. [19] Y. Jin, Z.Y. Zhou, W. Tian, Q. Yu, Y.Q. Long, 40-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(3',4',5'-substituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents, Bioorg. Med. Chem. Lett. 16 (2006) 5864-5869.[19] Y. Jin, Z.Y. Zhou, W. Tian, Q. Yu, Y.Q. Long, 40-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(3',4',5'-substituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents, Bioorg. Med. Chem. Lett. 16 (2006) 5864-5869.

  20. [20] D. Wobig, Thiazolderivate, Ⅲ. Reaktionen von cyanimidodithiocarbonaten mit achloracetamiden, Liebigs Ann. Chem. 1977 (1977) 400-406.[20] D. Wobig, Thiazolderivate, Ⅲ. Reaktionen von cyanimidodithiocarbonaten mit achloracetamiden, Liebigs Ann. Chem. 1977 (1977) 400-406.

  21. [21] The synthetic procedure and structure identification for compounds 2a-j, 4a-i and 4k-r are available in Supporting information. All synthesized final products were characterized by ¹H NMR, ¹³C NMR and ESI-HRMS. For example, compound 4a: light yellow solid; mp 179-182 ℃; ¹H NMR (300 MHz, DMSO-d₆): δ 10.77 (s, 1H), 8.27 (s, 1H), 7.79-7.89 (m, 3H), 7.58 (dd, 1H, J₁ = 8.7 Hz, J₂ = 2.1 Hz), 7.48 (t, 1H, J = 6.9 Hz), 7.38 (t, 1H, J = 7.2 Hz), 6.95 (brs, 2H), 4.14 (q, 2H, J = 6.9 Hz), 1.22 (t, 3H, J = 6.9 Hz); ¹³C NMR (100 MHz, DMSO-d₆): δ 165.04, 163.47, 137.56, 133.60, 129.41, 128.73, 127.53, 127.02, 126.61, 124.44, 119.59, 113.80, 58.97, 14.65; HRMS (ESI) Calcd. for C₁₆H₁₆N₃O₂S [M+H⁺]: 314.0958; found: 314.0957.[21] The synthetic procedure and structure identification for compounds 2a-j, 4a-i and 4k-r are available in Supporting information. All synthesized final products were characterized by ¹H NMR, ¹³C NMR and ESI-HRMS. For example, compound 4a: light yellow solid; mp 179-182 ℃; ¹H NMR (300 MHz, DMSO-d₆): δ 10.77 (s, 1H), 8.27 (s, 1H), 7.79-7.89 (m, 3H), 7.58 (dd, 1H, J₁ = 8.7 Hz, J₂ = 2.1 Hz), 7.48 (t, 1H, J = 6.9 Hz), 7.38 (t, 1H, J = 7.2 Hz), 6.95 (brs, 2H), 4.14 (q, 2H, J = 6.9 Hz), 1.22 (t, 3H, J = 6.9 Hz); ¹³C NMR (100 MHz, DMSO-d₆): δ 165.04, 163.47, 137.56, 133.60, 129.41, 128.73, 127.53, 127.02, 126.61, 124.44, 119.59, 113.80, 58.97, 14.65; HRMS (ESI) Calcd. for C₁₆H₁₆N₃O₂S [M+H⁺]: 314.0958; found: 314.0957.

•